Starling Oncology And 2 Other Growth Stocks Insiders Are Backing
The United States market has experienced a positive trajectory, climbing 2.2% in the last week and rising 21% over the past year, with earnings expected to grow by 17% annually. In such an environment, growth companies with high insider ownership can be particularly appealing as they often signal confidence from those closest to the business and may align well with favorable market conditions.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 13.9% | 66.5% |
| Precigen (PGEN) | 11.7% | 59.3% |
| Nu Holdings (NU) | 22.8% | 20.2% |
| Karman Holdings (KRMN) | 15.4% | 54% |
| Himax Technologies (HIMX) | 29.2% | 70.2% |
| Dave (DAVE) | 17.7% | 22.2% |
| Cerebras Systems (CBRS) | 11% | 73.7% |
| Carlyle Group (CG) | 27.7% | 20.5% |
| AppLovin (APP) | 23.3% | 20.6% |
| Almonty Industries (ALM) | 10.8% | 46% |
Let's dive into some prime choices out of the screener.
Starling Oncology (STLN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Starling Oncology, Inc. is an oncology company that offers a range of oncology services in the United States and has a market cap of approximately $653.28 million.
Operations: The company generates revenue through its segments: Patient Services ($237.95 million), Specialty Pharmacy ($343.46 million), and Clinical Trials & Other ($5.84 million).
Insider Ownership: 13.1%
Starling Oncology recently raised its earnings guidance for 2026, projecting revenue between $650 million and $670 million. The company reported significant revenue growth in Q2 2026 to US$161.28 million from US$119.8 million a year ago, with reduced net losses. Insider activity shows substantial buying over the past three months, suggesting confidence in future prospects. Despite high share price volatility, Starling is expected to achieve profitability within three years and exhibits strong relative value compared to peers.
- Click to explore a detailed breakdown of our findings in Starling Oncology's earnings growth report.
- Our expertly prepared valuation report Starling Oncology implies its share price may be lower than expected.
Cerebras Systems (CBRS)
Simply Wall St Growth Rating: ★★★★★★
Overview: Cerebras Systems Inc. is an artificial intelligence infrastructure company with a market cap of $51.36 billion.
Operations: The company's revenue is primarily generated from its semiconductors segment, totaling $603.89 million.
Insider Ownership: 11%
Cerebras Systems is expanding its AI capabilities through strategic partnerships and infrastructure growth, including a recent collaboration with Lovable to enhance software creation platforms using its Wafer-Scale Engine. Despite high share price volatility and significant insider selling recently, Cerebras shows robust revenue growth forecasts of 43.4% annually, outpacing the US market. The company's earnings are expected to grow at 73.7% per year, reflecting strong potential in AI-native markets despite trading below fair value estimates.
- Navigate through the intricacies of Cerebras Systems with our comprehensive analyst estimates report here.
- The analysis detailed in our Cerebras Systems valuation report hints at an deflated share price compared to its estimated value.
Karman Holdings (KRMN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Karman Holdings Inc., with a market cap of $7.72 billion, operates through its subsidiary to design, test, manufacture, and sell mission-critical systems in the United States.
Operations: KRMN generates revenue of $589.55 million from its operations in the Space and Defense Industry.
Insider Ownership: 15.4%
Karman Holdings demonstrates strong growth potential with earnings forecasted to grow 54% annually, significantly outpacing the US market. Recent Q2 results show a substantial increase in revenue and net income, while raised full-year guidance anticipates revenue between US$730 million and US$745 million. Despite high insider ownership, financial health concerns exist as interest payments aren't well-covered by earnings. Strategic expansions and acquisitions bolster its defense sector presence, supported by recent facility investments and index inclusions in the S&P Composite 1500.
- Take a closer look at Karman Holdings' potential here in our earnings growth report.
- Our comprehensive valuation report raises the possibility that Karman Holdings is priced higher than what may be justified by its financials.
Summing It All Up
- Delve into our full catalog of 174 Fast Growing US Companies With High Insider Ownership here.
- Want To Explore Some Alternatives? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com